Module 2

Whose idea is it anyway?

DATE: 8 December 2022 (16:00-18:00 GMT)

Genomics and biodata business ideas, and especially those emanating from research institutes, have intellectual property (IP). In this session we will look at:

  • Introduction to types of IP within genomics and biodata.
  • Patent or publish – what to do when you have an idea?
  • Who owns the IP you are developing as a researcher – what rights do you have?
  • How to create value from IP.
  • Pick up tools and frameworks to help you understand your IP position right from the start.
  • Explore the challenges of IP within software and when working with open and public data.

Birgit Kerber, Head of Innovation and Translation, EMBL-EBI

Birgit Kerber has been actively engaged in establishing technology transfer at the European Molecular Biology Laboratory (EMBL) more than 18 years ago and has since held various positions at EMBL’s technology transfer arm, EMBLEM. She is currently responsible for business development at the European Bioinformatics Institute (EMBL-EBI) and business development lead for Open Targets, a public-private partnership with EMBL-EBI, the Wellcome Sanger Institute, GSK, Takeda, BMS, and Sanofi. Birgit has been engaged in managing and licensing intellectual property with biotech and large pharma companies as customers as well as starting companies out of EMBL. She holds a diploma in biology from Philipps-University Marburg, did her Ph.D. work at the Max-Planck-Institute for biophysical chemistry in Goettingen, and a postdoc at EMBL Heidelberg. She is a member of BIO Deutschland and the Licensing Executives Society as well as an alumna of St Gallen Business School, CEIPI, Boehringer Ingelheim Fonds, DFG, and EMBO.

Adrian Ibrahim, Head of Innovation and Translation, Wellcome Sanger Institute

Adrian joined the Sanger Institute in 2011 to establish its Technology Translation Office. With a background spanning academic research, structured finance and technology protection, development and commercialisation, Adrian was recruited to optimise the ability of Sanger Institute science to provide healthcare benefit. Adrian’s tenure at Sanger has driven significant expansion and maturation of the Institute's spin out portfolio - including companies working in the cancer genomics, rare disease analytics and microbiome therapeutics fields; establishment of the 50 FTE Open Targets programme; execution of licensing deals with major strategic benefits for the exploitation of key Institute assets; and successful establishment of the BioData Innovation Centre to increase Campus engagement with innovative Genome and Biodata companies. Adrian is the inaugural chair of the BioIndustry Association’s Genomics Advisory Committee which seeks to shape UK policy for innovative genomics companies.

Gary P. Dillon, Business Development Manager, Wellcome Sanger Institute

Gary obtained his BSc. in Biochemistry at York in 2002, going on to study a Ph.D. in Parasitology, also at York. As a post-doc, he worked at the Wellcome Sanger Institute, before moving to Abcam in 2010. Gary became Abcam’s Head of R&D in 2013, a role that bridged science and business during a period of rapid growth for the company. In this context, Gary directed teams from across the globe, and across scientific biological and chemistry disciplines to develop some of Abcam’s most difficult to derive products (e.g. anti-RNA modifications). Working closely with commercial teams to Gary also helped to build business cases that set company R&D strategy, and provided technical due diligence for acquisitions (e.g. AxioMx) and IP. He has now returned to the Wellcome Sanger Institute to apply his industrial experience by helping scientists commercialise and share their ideas for the benefit of society.

Mariya Chhatriwala, Business develeopment Manager, Wellcome Sanger Institute
Mariya Chhatriwala, Business Development Associate, Wellcome Sanger Institute

Mariya is a post-doctoral level scientist with over 10 years of hands-on experience in various scientific disciplines including genetic regulation, stem cell biology, next-generation sequencing, and protein biochemistry. She joined the Sanger in 2013 as a staff scientist and transitioned into the role of senior scientific manager.  In 2019, she joined the Innovation and Enterprise team at the Sanger to leverage her scientific expertise toward successful commercial development and dissemination of the cutting-edge research taking place at the Institute as she believes this is the best way for these ideas to contribute to healthcare solutions.

Agnieszka Wabik, Business Development Associate, Wellcome Sanger Institute

Aga obtained her BSc in Genetics from Edinburgh University and PhD in Cancer and Stem Cells at the University of Cambridge. Part of her PhD and a short post-doc work took place at Wellcome Sanger Institute. Throughout her academic and extracurricular work at Cambridge, she was actively involved in the Cambridge Cluster. During her PhD, she joined the Global Innovation Forum Ltd, where she acted as COO for the Innovation Leaders Conference bringing together industry executives, entrepreneurs, scientists and policymakers and set up the Imagine IF! Business Idea Competition. After her PhD, she went on supporting the development and implementation of the scientific strategy while working at the Experimental Cancer Medicines Centres Network at Cancer Research UK. Aga has now returned to the Wellcome Sanger Institute following her passion for science where she leverages her scientific background and previous expertise to help scientists commercialise and share their ideas to provide cutting edge healthcare solutions.